title: Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
abstract: FLT3 receptor tyrosine kinase is aberrantly active in many cases of acute myeloid leukemia (AML). Recently, bis(1H-indol-2-yl)methanones were found to inhibit FLT3 and PDGFR kinases. To optimize FLT3 activity and selectivity, 35 novel derivatives were synthesized and tested for inhibition of FLT3 and PDGFR autophosphorylation. The most potent FLT3 inhibitors 98 and 102 show IC50 values of 0.06 and 0.04 microM, respectively, and 1 order of magnitude lower PDGFR inhibiting activity. The derivatives 76 and 82 are 20- to 40-fold PDGFR selective. Docking at the recent FLT3 structure suggests a bidentate binding mode with the backbone of Cys-694. Activity and selectivity can be related to interactions of one indole moiety with a hydrophobic pocket including Phe-691, the only different binding site residue (PDGFR Thr-681). Compound 102 inhibited the proliferation of 32D cells expressing wildtype FLT3 or FLT3-ITD similarly as FLT3 autophosphorylation, and induced apoptosis in primary AML patient blasts.
authors.affiliation: Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, D-93040 Regensburg, Germany. siavosh.mahboobi@chemie.uni-regensburg.de
authors.forename: Siavosh
authors.initials: S
authors.lastname: Mahboobi
authors.forename: Andrea
authors.initials: A
authors.lastname: Uecker
authors.forename: Andreas
authors.initials: A
authors.lastname: Sellmer
authors.forename: Christophe
authors.initials: C
authors.lastname: Cénac
authors.forename: Heymo
authors.initials: H
authors.lastname: Höcher
authors.forename: Herwig
authors.initials: H
authors.lastname: Pongratz
authors.forename: Emerich
authors.initials: E
authors.lastname: Eichhorn
authors.forename: Harald
authors.initials: H
authors.lastname: Hufsky
authors.forename: Antje
authors.initials: A
authors.lastname: Trümpler
authors.forename: Marit
authors.initials: M
authors.lastname: Sicker
authors.forename: Florian
authors.initials: F
authors.lastname: Heidel
authors.forename: Thomas
authors.initials: T
authors.lastname: Fischer
authors.forename: Carol
authors.initials: C
authors.lastname: Stocking
authors.forename: Sigurd
authors.initials: S
authors.lastname: Elz
authors.forename: Frank-D
authors.initials: FD
authors.lastname: Böhmer
authors.forename: Stefan
authors.initials: S
authors.lastname: Dove
mesh_terms: D000208:Acute Disease; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D017209:Apoptosis; D001665:Binding Sites; D002460:Cell Line; D045744:Cell Line, Tumor; D006801:Humans; D066298:In Vitro Techniques; D007211:Indoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D007951:Leukemia, Myeloid / Q000097:blood / Q000473:pathology; D008024:Ligands; D051379:Mice; D008958:Models, Molecular; D010766:Phosphorylation; D011758:Pyrroles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D008024:Ligands; D011758:Pyrroles; C116890:Semaxinib; C099852:PDGF receptor tyrosine kinase; D017479:Receptors, Platelet-Derived Growth Factor; D051941:fms-Like Tyrosine Kinase 3